Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT2 | Q96PD7 | 1/20 | 0.33 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.32 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19286458 | 0.88 | DGAT2 (0.33) | DGAT2RET | |
| SCHEMBL6508680 | 0.82 | RET (0.32) | DGAT2CYP4F2CYP4A11RET | |
| SCHEMBL30124206 | 0.82 | RET (0.32) | DGAT2CYP4F2CYP4A11RET | |
| SCHEMBL25029056 | 0.79 | CYP4F2 (0.35) | DGAT2CYP4F2CYP4A11RET | |
| SCHEMBL26926865 | 0.79 | DGAT2 (0.32) | DGAT2 | |
| SCHEMBL17588937 | 0.78 | RXRA (0.42) | CYP4F2CYP4A11 | |
| SCHEMBL29005738 | 0.76 | LMNA (0.33) | DGAT2CYP4F2CYP4A11 | |
| SCHEMBL29168327 | 0.76 | DGAT2 (0.36) | DGAT2CYP4F2CYP4A11RET | |
| SCHEMBL29168318 | 0.76 | RXRA (0.42) | CYP4F2CYP4A11 | |
| SCHEMBL12370608 | 0.75 | CYP4F2 (0.33) | CYP4F2CYP4A11RET |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10023572-B2 | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-07-17 | — | — | US | disclosed |
| US-10023572-B2 | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof | SAMUMED, LLC (US) | 2018-07-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10023572-B2 | 2-(1h-indazol-3-yl)-3h-imidazo[4,5-b]pyridine and therapeutic uses thereof | WNT1, WNT3, WNT3A | DGAT2 4173/4885CYP4F2 2985/4885CYP4A11 1793/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.